Astodrimer

Drug Profile

Astodrimer

Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; BRI-7013; SPL-7013; SPL7013 vaginal gel; VivaGel

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biomolecular Research Institute
  • Developer Starpharma
  • Class Antibacterials; Antivirals; Dendrimers; Peptides
  • Mechanism of Action Anion transport protein modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Bacterial vaginosis
  • Phase I/II Herpes simplex virus infections; HIV infections
  • Research Human papillomavirus infections; Zika virus infection

Most Recent Events

  • 07 Aug 2017 Starpharma announces intention to submit NDA to US FDA for Bacterial vaginosis
  • 07 Aug 2017 Efficacy data from the two phase III trials in Bacterial vaginosis (Prevention) released by Starpharma
  • 11 Jan 2017 Astodrimer receives Fast Track designation for Bacterial vaginosis [Vaginal,Gel] (Prevention, Treatment) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top